Skip to main content
. 2015 Sep 29;5:14554. doi: 10.1038/srep14554

Figure 4. E. coli decreases the efficacy of gemcitabine in vivo.

Figure 4

Subcutaneous flank CT26 tumours growing in Balb/c mice were injected i.t with bacteria or PBS vehicle alone. Gemcitabine (60 mg/kg) was injected i.p. five times at three day intervals. (a) Tumour volume (%) relative to the first day of gemcitabine injection (day 0) is shown. *P < 0.03, **P = 0.002 (Bonferroni post hoc test) for gemcitabine alone versus gemcitabine + bacteria. (b) Kaplan-Meier plots showing mouse survival over time. The median survival post Day 0 of the gemcitabine + bacteria group was significantly less than that of the gemcitabine alone group (17 days vs. 28 days +/−1.25; P = 0.008). Data are expressed as mean ± SEM of 4 to 8 individual mice per group.